Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults.
about
Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adultsOptimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adultsFeasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV indicator diseases across Europe study)The prevalence of transmitted resistance to first-generation non-nucleoside reverse transcriptase inhibitors and its potential economic impact in HIV-infected patientsThe impact of monitoring HIV patients prior to treatment in resource-poor settings: insights from mathematical modellingModeling the cost-effectiveness of HIV treatment: how to buy the most 'health' when resources are limited.Early HIV treatment in the United States prevented nearly 13,500 infections per year during 1996-2009Timing Matters: HIV Testing Rates in the Emergency Department.HIV treatment as prevention: modelling the cost of antiretroviral treatment--state of the art and future directions.Late presenters among persons with a new HIV diagnosis in Italy, 2010-2011.When to start antiretroviral therapy: the need for an evidence base during early HIV infectionInfluence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: a decision model.Auditing HIV Testing Rates across Europe: Results from the HIDES 2 Study.Balancing immunological benefits and cardiovascular risks of antiretroviral therapy: when is immediate treatment optimal?Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trialProviders' perceptions of the factors influencing the implementation of the New York State mandatory HIV testing law in two Urban academic emergency departmentsA systematic review of cost-utility analyses in HIV/AIDS: implications for public policy.Indicator disease-guided testing for HIV--the next step for Europe?Cost of hospital care for HIV/AIDS infected patients in three general reference hospitals in Lubumbashi, DR Congo: prospective cohort studyAn electronic alert for HIV screening in the emergency department increases screening but not the diagnosis of HIV.A review of economic evaluations of darunavir boosted by low-dose ritonavir in treatment-experienced persons living with HIV infection.Pharmacoeconomics of darunavir.Cost-effectiveness of targeted human immunodeficiency virus screening in an urban emergency department.Trigger-oriented HIV testing at Internal Medicine hospital Departments in Northern Italy: an observational study (Fo.C.S. Study).Efficacy, safety, and tolerability of long-term combination antiretroviral therapy in asymptomatic treatment-naïve adults with early HIV infection.Distribution of health care expenditures for HIV-infected patients.A microsimulation of the cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals.Utilities derived from visual analog scale scores in patients with HIV/AIDS.Mean cost of a first combination antiretroviral therapy in HIV-infected patients in France, and determinants of expensive drugs prescription
P2860
Q24236739-C480FE8B-0BD7-4EA8-81FA-9206ECE79FFEQ24241255-7D998A4F-3730-4FFD-BDB8-45F83901A26FQ28485122-DF79DF7A-42AD-4F77-A97C-4877BCC84B4DQ28535577-A9AB58C1-7EFF-40EE-B347-F3F1D3116890Q33323442-3717FA86-B1C1-44F3-B16F-9CDE0DC93D7AQ33854542-50A37B0A-AD97-41EE-8DFD-B7B081BA5459Q34014700-42534020-88F9-4DC6-AAE3-4ADF8B7B05D8Q34247318-AA6042C9-0195-45C4-BC19-5DB720E030B9Q34339471-55E8888C-4E5E-4BE3-8714-7949E74DA2EAQ34640437-85D8D4A0-9641-4694-A496-E4FB18B811E4Q34773308-E3C02E26-63EC-41AC-8E50-469891B02FAEQ35070832-DED8FCE7-BE58-4165-BD2B-1227E42B4C20Q35839025-D341AB07-F5D8-4607-B13B-65C026B5AAE5Q36338387-D88795ED-1766-4D01-AE40-BE8B4F83F201Q36627942-377F6BA9-83DE-4E58-B978-EA242CCF3825Q36716252-94FDA9B0-A623-4BEC-98CA-ECA91FD6017BQ37023469-8D065986-20A7-4404-A119-562081DB0F46Q37192570-5F9C4522-03DF-4766-972A-43C1C13EB383Q37260260-5C3BDFAA-6FE8-4194-AFC7-30D2D23D13C5Q37682098-C15342AD-7F79-452E-A9A5-08809F3D2C89Q37823555-7DA1CB7B-5192-4BE7-BC0A-8ECCC81BAEF4Q37847151-A35D6981-5263-48D4-B1C3-0AC2C58CE040Q37901537-6ABEEA50-AF23-42D8-B2F1-CA48D5E3446AQ38936029-D0E0AFAC-E776-4850-977C-F7D365BB6218Q42635373-77B0E9C9-9B7E-43FD-B4CB-DB3F05B861E3Q42699465-FAD853FC-44FA-40CD-AFC3-47D494EE5F3FQ43027648-69685F21-3B71-480F-9AD7-175E0C6094E5Q47431983-D2F76F3D-F1DB-46BD-93BA-9882EBBC6C0AQ56449099-98526113-FC02-4BE3-8454-C23B07F2CEDA
P2860
Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Cost-effectiveness implication ...... herapy in HIV-infected adults.
@en
Cost-effectiveness implication ...... herapy in HIV-infected adults.
@nl
type
label
Cost-effectiveness implication ...... herapy in HIV-infected adults.
@en
Cost-effectiveness implication ...... herapy in HIV-infected adults.
@nl
prefLabel
Cost-effectiveness implication ...... herapy in HIV-infected adults.
@en
Cost-effectiveness implication ...... herapy in HIV-infected adults.
@nl
P2093
P50
P1476
Cost-effectiveness implication ...... herapy in HIV-infected adults.
@en
P2093
Bruce R Schackman
Hong Zhang
Paul E Sax
P304
P356
10.1001/ARCHINTE.162.21.2478
P407
P577
2002-11-01T00:00:00Z